Sulfo-Cyanine5.5 NHS ester
Cat. # | Quantity | Price | Lead time | Buy this product |
---|---|---|---|---|
17320 | 1 mg | $110.00 | in stock | |
27320 | 5 mg | $290.00 | in stock | |
47320 | 25 mg |
$690.00
|
in stock | |
57320 | 50 mg |
$1190.00
|
in stock | |
67320 | 100 mg |
$1850.00
|
in stock |
Sulfo-Cyanine5.5 NHS ester is an amine reactive activated ester of sulfonated far red Cyanine5.5 fluorophore, an analog of Cy5.5®. This is a reagent of choice for the labeling of antibodies, sensitive proteins, and others which require reactions in purely aqueous environment, or without any significant additions of organic co-solvents.
The dye is well suitable for non-invasive in vivo NIR imaging, and for the applications requiring low fluorescent background.
Absorption and emission spectra of sulfo-Cyanine5.5 fluorophore

Recommended protocol
Calculator
Customers also purchased with this product
Cyanine5 maleimide
Cyanine5 maleimide reacts with thiols to give dye labeled conjugates.get free express delivery
EDC, coupling grade
Water soluble carbodiimide for the coupling of carboxylic acids with amines.TAMRA amine, 5-isomer
TAMRA (tetramethylrhodamine) dye, pure 5-isomer, with an amine group for the conjugation with electrophilic reagents (NHS esters, epoxides, etc).get free express delivery
General properties
Appearance: | dark blue solid |
Mass spec M+ increment: | 884.15 |
Molecular weight: | 1114.37 |
Molecular formula: | C44H42N3K3O16S4 |
Solubility: | good in water, DMF, DMSO |
Quality control: | NMR 1H, HPLC-MS (95%) |
Storage conditions: | Storage: 12 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Avoid prolonged exposure to light. Desiccate. |
MSDS: | Download |
Product specifications |
Spectral properties
Excitation/absorption maximum, nm: | 675 |
ε, L⋅mol−1⋅cm−1: | 235000 |
Emission maximum, nm: | 694 |
CF260: | 0.09 |
CF280: | 0.11 |
Product citations
- Lu, Z.; Zhang, Y.; Wang, Y.; Tan, G.-H.; Huang, F.-Y.; Cao, R.; He, N.; Zhang, L. A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy. Journal of Controlled Release, in press. doi: 10.1016/j.jconrel.2021.02.029
- Shramova, E.; Proshkina, G.; Shipunova, V.; Ryabova, A.; Kamyshinsky, R.; Konevega, A.; Schulga, A.; Konovalova, E.; Telegin, G.; Deyev, S. Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape. Cancers, 2020, 12(10), 3014. doi: 10.3390/cancers12103014
- Peplau, E.; De Rose, F.; Reder, S.; Mittelhaeuser, M.; Scafetta, G.; Schwaiger, M.; Weber, W.A.; Bartolazzi, A.; Skerra, A.; D'Alessandria, C. Development of a chimeric Fab directed against human galectin-3 and validation as an immune-PET tracer for the sensitive in vivo imaging of thyroid cancer. Thyroid, 2020, 30(9), 1314–1326. doi: 10.1089/thy.2019.0670
- Sim, T.; Lim, C.; Hoang, N.H.; Shin, Y.; Kim, J.C.; Park, J.Y.; Her, J.; Lee, E.S.; Youn, Y.S.; Oh, K.T. An On-Demand pH-Sensitive Nanocluster for Cancer Treatment by Combining Photothermal Therapy and Chemotherapy. Pharmaceutics, 2020, 12, 839. doi: 10.3390/pharmaceutics12090839
